Success Metrics

Clinical Success Rate

33.3%

Based on 1 completed trials

Completion Rate

33%(1/3)

Active Trials

1(25%)

Results Posted

400%(4 trials)

Terminated

2(50%)

Phase Distribution

Ph phase_1

50%

Ph phase_2

50%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution4 total trials

Phase 1Safety & dosage

2(50.0%)

Phase 2Efficacy & side effects

2(50.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

33.3%

1 of 3 finished

Non-Completion Rate

66.7%

2 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(1)

Completed(1)

Terminated(2)

Detailed Status

Terminated2

Active, not recruiting1

Completed1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

33.3%

Most Advanced

Phase 2

Trials by Phase

Phase 12 (50.0%)

Phase 22 (50.0%)

Trials by Status

terminated250%

active_not_recruiting125%

completed125%

Recent Activity

1 active trials

Showing 4 of 4

active_not_recruitingphase_2

TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies

NCT03849651

completedphase_2

Clinical Trials (4)

Showing 4 of 4 trials

NCT03849651Phase 2

TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies

Active Not Recruiting

NCT01104025Phase 2

Hybrid Immunotherapy for Hemophagocytic LymphoHistiocytosis

Completed

NCT00424489Phase 1

Hematopoietic Stem Cell Therapy for Patients With Refractory Myasthenia Gravis

Terminated

NCT00278512Phase 1

Hematopoietic Stem Cell Support in Vasculitis

Terminated

All 4 trials loaded

Drug Details

Intervention Type: BIOLOGICAL
Total Trials: 4